Navigation Links
Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
Date:2/11/2008

and commercial milestones in international markets. Schering-Plough will also provide promotional support for the product in international markets. All sales of the HCV test will be made by OraSure, and OraSure will retain the rights to market and sell the test in all markets throughout the world. During the collaboration period, the test may, at Schering-Plough's option, be labeled and promoted under both Schering-Plough and OraSure trademarks.

Schering-Plough is committed to advancing the science and treatment of hepatitis C, both in terms of its internal research and development programs, and by collaborating with other companies. In addition, Schering-Plough is committed to supporting hepatitis C patients through its leading disease awareness, education and service programs.

Approximately 170 million people are chronically infected with hepatitis C worldwide and there are approximately 3 to 4 million new HCV infections each year on a global basis. Chronic hepatitis C can cause cirrhosis, liver failure and liver cancer. About half of all cases of primary liver cancer in the developed world are caused by hepatitis C, and hepatitis C related liver disease is now the leading cause for liver transplants. Most people who develop chronic hepatitis C infection are not aware that they have the disease.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

In addition, OraSure sells products for the cryosurgical removal of common and pla
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
2. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
3. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
4. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
5. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
6. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
7. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
8. Schering-Plough Completes Acquisition of Organon BioSciences
9. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
10. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
11. Schering-Plough Announces Pricing of Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
(Date:9/19/2014)... -- The new , Healthcare and Life Sciences ... on PharmaBoardroom.com for free download , looks ... Spanish economy in 2009, and the austerity measures that followed, ... in times of trouble. "Despite the crisis, ... market, and the general conditions to invest are favorable to ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 ... urological and interventional radiology products and services, announced ... as cryotherapy and cryoablation) versus external beam radiotherapy ... of the American Urological Association (MAAUA) Annual Meeting ... "Comparing Relative Effectiveness of Cryosurgery and External Beam ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Acetic Acid Industry" and "2014 Deep Research ... reports to its research database. Photo ... Deep Research Report on Global and China Acetic ... report on China and ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4
... Calif., May 20 Beckman Coulter, Inc. (NYSE: ... of products that simplify, automate and innovate complex biomedical ... of shares of its common stock, the proceeds of ... the previously announced acquisition of the diagnostic systems portion ...
... - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... partner, Boston Scientific Corporation (NYSE: BSX ... of patients with left main coronary disease who ... Stent System. SYNTAX-LE MANS is a substudy of ...
... In an eleventh-hour attempt to smear Ted Karkus, The ... press release claiming that there was some improper financial arrangement ... subsidiary of Quigley, and Mr. Ted Karkus, who leads a ... of Quigley,s Board of Directors for election at the annual ...
Cached Biology Technology:Beckman Coulter, Inc. Announces Pricing of Common Stock Offering 2Beckman Coulter, Inc. Announces Pricing of Common Stock Offering 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 2SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 4SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 5In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3
(Date:9/18/2014)... located deep in the primitive brainstem has revealed how ... Harvard School of Medicine and the University at Buffalo ... the second "sleep node" identified in the mammalian brain ... to produce deep sleep. , Published online in August ... fully half of all of the brain,s sleep-promoting activity ...
(Date:9/18/2014)... novel robotic system that can operate inside the bore ... part of a biomedical research partnership program at Brigham ... determining if the robot, in conjunction with real-time MRI ... less costly, and less discomforting for the patient. The ... cancer therapies with greater precision. , Developed by a ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, it,s ... creatures. , But by using a signaling ... alter their behavior to suit their population. In ... are present, and act accordingly. , Once the ... may change from innocuous to pathogenic, or from ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... female frogs in a tiny rainforest outpost of Australia ... 8,000 years or less, according to scientists from the ... the Queensland Parks and Wildlife Service. , "That's lightning-fast," ... UC Berkeley and director of the Museum of Vertebrate ...
... culminated in a study published in this week's Science that ... or prevent East Coast fever. , The disease, which kills ... has had a devastating impact on rural areas ?such as ... role in the local society and economies. The fever is ...
... a single gene can result in two immune ... frequent or unusually severe infections, according to new ... Genetics. The discovery may lead to new diagnostic ... (IgA) deficiency and common variable immunodeficiency (CVID). Currently, ...
Cached Biology News:Picky female frogs drive evolution of new species in less than 8,000 years 2Picky female frogs drive evolution of new species in less than 8,000 years 3Picky female frogs drive evolution of new species in less than 8,000 years 4US/African project deciphers deadly parasite genome 2US/African project deciphers deadly parasite genome 3Defective Gene Linked to Two Inherited Immune Deficiencies 2Defective Gene Linked to Two Inherited Immune Deficiencies 3
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
...
Biology Products: